About Genprex (GNPX)

Genprex Inc (GNPX) is a biopharmaceutical company focused on developing targeted molecular therapies for the treatment of cancer. The company's lead product candidate is REQORSA™ immunogene therapy, which is being evaluated in clinical trials for the treatment of non-small cell lung cancer (NSCLC). REQORSA™ is designed to inhibit the signaling pathways that contribute to cancer cell growth and survival, potentially leading to improved patient outcomes. Genprex is also developing a diabetes gene therapy program, which aims to provide a long-term solution for patients with insulin-dependent diabetes.

GNPX stock has shown significant volatility in its price history. Over the past year, the stock has traded in a range of $1.50 to $9.00 per share. The current market capitalization of Genprex Inc is approximately $250 million. The company has a PEG ratio of 0.80, indicating that the stock may be undervalued compared to its expected earnings growth. When comparing Genprex Inc to its industry peers, it is important to note that the company operates in the biopharmaceutical sector, which is known for its high levels of innovation and risk. Investors should carefully consider these factors when evaluating the stock's potential for future growth.